 "Alembic Pharma gets USFDA nod for generic Adapalene gel for acne treatment")
Alembic Pharmaceuticals on Friday said its joint venture had received nod from the US health regulator for generic Adapalene gel used for the treatment of acne.
The company's JV Aleor Dermaceuticals has received approval from the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Adapalene gel USP, 0.3 per cent, Alembic Pharma said in a filing to the BSE.
The approved product is a generic version of Galderma Laboratories LP's Differin gel in the same strength, it added.
According to IQVIA, Adapalene gel USP, 0.3 per cent, has an estimated market size of $34 million for twelve months ending March 2020, Alembic Pharma said.
The product is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, it added.
The company has a cumulative total of 123 ANDA approvals (110 final approvals and 13 tentative approvals) from USFDA, Alembic Pharma said.
Shares of Alembic Pharmaceuticals were trading at Rs 934.20 per scrip on the BSE, up 2.85 per cent over previous close.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%